The 3 references without contexts in paper V. Perfiliev Y., Y. Zverev F., A. Zharikov Y., D. Lukiyanenko Y., I. Lysenko V., O. Atabaeva S., В. Перфильев Ю., Я. Зверев Ф., А. Жариков Ю., Д. Лукьяненко Ю., И. Лысенко В., О. Атабаева Ш. (2017) “ОПЫТ ПРИМЕНЕНИЯ ПИОГЛИТАЗОНА ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ЭКСПЕРИМЕНТАЛЬНОГО УРАТНОГО НЕФРОЛИТИАЗА // EXPERIENCE WITH THE USE OF PIOGLITAZONE FOR THE PREVENTION AND TREATMENT OF EXPERIMENTAL URATE NEPHROLITHIASIS” / spz:neicon:nefr:y:2017:i:1:p:52-56

10
Abate N, Chandalia M, Cabo-Chan AV Jr et al. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int 2004; 65: 386-392
(check this in PDF content)
11
Cameron MA, Maalouf NM, Adams-Huet B et al. Urine composition in type 2 diabetes: predisposition to uric acid nephrolithiasis. J Am Soc Nephrol 2006; 17: 1422-1428
(check this in PDF content)
19
1PS@mail.ru Perfi lev Y. Vyacheslav Affi liations: 656038, Russia, Barnaul, Lenin Avenue 40, Altai State Medical University, Department of Pharmacology. Phone: +7 (3852) 24-18-59, +7 (923) 566-52-45, E-mail 1991PS@mail.ru
(check this in PDF content)